For clinician-administered drugs, researchers find no association between price increases and OOP cost increases
It seems obvious to assume that patient out-of-pocket costs would increase as drug companies raise the prices of their drugs. But a new study published …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
